Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis through its anti-inflammatory activity
2024

Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): Lee Yu Jeong, Li Zijun, Jang Hyun Hee, Kim Moon-Ju, Saravanakumar Kandasamy, Shim Seung Cheol, Cho Namki, Won Eun Jeong, Kim Tae-Jong

Primary Institution: Chonnam National University

Hypothesis

This study aimed to evaluate the potential anti-inflammatory effects of Usenamine A (UA) and its therapeutic effects on rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

Conclusion

Usenamine A has potential as a therapeutic agent that suppresses inflammatory cytokines and exhibits anti-inflammatory effects on arthritis.

Supporting Evidence

  • Usenamine A did not affect cell viability in PBMCs from RA and AS patients.
  • UA treatment significantly reduced the levels of inflammatory cytokines in PBMCs from RA and AS patients.
  • In an arthritis mouse model, UA treatment resulted in significantly reduced clinical and histological scores.

Takeaway

Usenamine A might help people with arthritis by reducing inflammation in their bodies.

Methodology

The study involved molecular docking, treatment of peripheral blood mononuclear cells (PBMCs) from RA and AS patients with UA, and evaluation of its effects in an arthritis mouse model.

Limitations

Further research is necessary to elucidate the specific mechanisms of UA’s anti-inflammatory actions post-docking and more samples from RA and AS patients are needed.

Participant Demographics

{"RA":{"total":9,"age_mean":53.8,"male_percentage":33.3},"AS":{"total":9,"age_mean":43.4,"male_percentage":66.6}}

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fphar.2024.1456216

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication